Literature DB >> 6781809

Determination of mean valproic acid serum level by assay of a single pooled sample.

R A Hamilton, W R Garnett, B J Kline.   

Abstract

Determinations of single serum drug concentrations are useful in monitoring drug therapy. A mean serum level would supply more information but is expensive and laborious because of the multiple blood samples and assays, calculation of area under the curve (AUC) by the trapezoidal rule, and division of the AUC by the time interval during which the samples were drawn. A method was devised that pools aliquots from individual serum samples taken during the testing period to form on composite sample. A single assay of this sample provides the mean serum level of the testing period. The method was successfully tested with amaranth and then applied to valproic acid serum levels. AUC and mean serum levels were determined by the standard procedure of assays of multiple samples and the trapezoidal rule. Mean serum level was also determined by the pooled sample technique. The correlation coefficient for the comparison of the mean serum levels determined by the two techniques is 0.907 (p less than 0.001). There was no difference between the estimates of the mean serum levels by Student's paired t test (t = 0.693, p greater than 0.2). The good correlation and lack of difference between the conventional method and the pooled sample method indicates that the method is valid.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 6781809     DOI: 10.1038/clpt.1981.56

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  15 in total

1.  Human mass balance study of TAS-102 using (14)C analyzed by accelerator mass spectrometry.

Authors:  James J Lee; Jabed Seraj; Kenichiro Yoshida; Hirokazu Mizuguchi; Sandra Strychor; Jillian Fiejdasz; Tyeler Faulkner; Robert A Parise; Patrick Fawcett; Laura Pollice; Scott Mason; Jeremy Hague; Marie Croft; James Nugteren; Charles Tedder; Weijing Sun; Edward Chu; Jan Hendrik Beumer
Journal:  Cancer Chemother Pharmacol       Date:  2016-01-19       Impact factor: 3.333

2.  The influence of orally deposited budesonide on the systemic availability of budesonide after inhalation from a Turbuhaler.

Authors:  S Pedersen; G Steffensen; S V Ohlsson
Journal:  Br J Clin Pharmacol       Date:  1993-09       Impact factor: 4.335

3.  First-in-humans study of the safety, tolerability, and pharmacokinetics of ACT-451840, a new chemical entity with antimalarial activity.

Authors:  Shirin Bruderer; Noémie Hurst; Ruben de Kanter; Tommaso Miraval; Thomas Pfeifer; Yves Donazzolo; Jasper Dingemanse
Journal:  Antimicrob Agents Chemother       Date:  2014-11-24       Impact factor: 5.191

4.  Absorption, metabolism and excretion of [14C]-sotorasib in healthy male subjects: characterization of metabolites and a minor albumin-sotorasib conjugate.

Authors:  Irene Vuu; Upendra P Dahal; Zhe Wang; Xiaomeng Shen; John Rodgers; Jan Wahlstrom; Brett Houk
Journal:  Cancer Chemother Pharmacol       Date:  2022-09-05       Impact factor: 3.288

5.  Dose-dependent acute liver injury with hypersensitivity features in humans due to a novel microsomal prostaglandin E synthase 1 inhibitor.

Authors:  Yan Jin; Arie Regev; Jeanelle Kam; Krista Phipps; Claire Smith; Judith Henck; Kristina Campanale; Leijun Hu; D Greg Hall; Xiao Yan Yang; Masako Nakano; Terry Ann McNearney; Jack Uetrecht; William Landschulz
Journal:  Br J Clin Pharmacol       Date:  2017-10-08       Impact factor: 4.335

6.  Pharmacokinetics of budesonide in children with asthma.

Authors:  S Pedersen; G Steffensen; I Ekman; M Tönnesson; O Borgå
Journal:  Eur J Clin Pharmacol       Date:  1987       Impact factor: 2.953

7.  Identification of cryptolepine metabolites in rat and human hepatocytes and metabolism and pharmacokinetics of cryptolepine in Sprague Dawley rats.

Authors:  Arnold Donkor Forkuo; Charles Ansah; David Pearson; Werner Gertsch; Amanda Cirello; Adam Amaral; Jaimie Spear; Colin W Wright; Caroline Rynn
Journal:  BMC Pharmacol Toxicol       Date:  2017-12-22       Impact factor: 2.483

8.  Absorption, distribution, metabolism, and excretion of [14C]-dasotraline in humans.

Authors:  Yu-Luan Chen; Estela Skende; Jing Lin; Yijun Yi; Peter L Wang; Sarah Wills; H Scott Wilkinson; Kenneth S Koblan; Seth C Hopkins
Journal:  Pharmacol Res Perspect       Date:  2016-12-18

9.  Evaluation of absorption, distribution, metabolism, and excretion of [14C]-rucaparib, a poly(ADP-ribose) polymerase inhibitor, in patients with advanced solid tumors.

Authors:  Mingxiang Liao; Simon Watkins; Eileen Nash; Jeff Isaacson; Jeff Etter; Jeri Beltman; Rong Fan; Li Shen; Abdul Mutlib; Vendel Kemeny; Zsuzsanna Pápai; Pascal van Tilburg; Jim J Xiao
Journal:  Invest New Drugs       Date:  2019-06-27       Impact factor: 3.850

10.  Proof of Concept: First Pediatric [14 C]microtracer Study to Create Metabolite Profiles of Midazolam.

Authors:  Bianca D van Groen; Esther van Duijn; Arjan de Vries; Miriam G Mooij; Dick Tibboel; Wouter H J Vaes; Saskia N de Wildt
Journal:  Clin Pharmacol Ther       Date:  2020-06-27       Impact factor: 6.875

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.